DWTX

$0.00

(

+0.00%

)
Quote details

stock

Dogwood Therapeutics, Inc.

NASDAQ | DWTX

5.67

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 17, 2025)

$12.77M

Market Cap

-

P/E Ratio

-25.59

EPS

$21.78

52 Week High

$1.76

52 Week Low

HEALTHCARE

Sector

DWTX Chart

Recent Chart
Price Action

DWTX Technicals

Tags:

DWTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$12K
Total Revenue $0
Cost Of Revenue $12K
Costof Goods And Services Sold $12K
Operating Income -$12M
Selling General And Administrative $8.7M
Research And Development $3.5M
Operating Expenses $12M
Investment Income Net -
Net Interest Income -$92K
Interest Income -
Interest Expense $92K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $12K
Income Before Tax -$12M
Income Tax Expense -$503
Interest And Debt Expense -
Net Income From Continuing Operations -$12M
Comprehensive Income Net Of Tax -
Ebit -$12M
Ebitda -$12M
Net Income -$12M

Revenue & Profitability

Earnings Performance

DWTX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $94M
Total Current Assets $17M
Cash And Cash Equivalents At Carrying Value $15M
Cash And Short Term Investments $15M
Inventory -
Current Net Receivables -
Total Non Current Assets $78M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $66M
Intangible Assets Excluding Goodwill $66M
Goodwill $12M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.7M
Other Non Current Assets -
Total Liabilities $30M
Total Current Liabilities $3.2M
Current Accounts Payable $1.2M
Deferred Revenue -
Current Debt -
Short Term Debt $99K
Total Non Current Liabilities $27M
Capital Lease Obligations $205K
Long Term Debt $15M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $16M
Other Current Liabilities $1.8M
Other Non Current Liabilities -
Total Shareholder Equity $64M
Treasury Stock -
Retained Earnings -$74M
Common Stock $133
Common Stock Shares Outstanding $1M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$8.8M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $12K
Capital Expenditures $5
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $3.8M
Cashflow From Financing $17M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$351
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$12M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$12K
Total Revenue $0
Cost Of Revenue $12K
Costof Goods And Services Sold $12K
Operating Income -$12M
Selling General And Administrative $8.7M
Research And Development $3.5M
Operating Expenses $12M
Investment Income Net -
Net Interest Income -$92K
Interest Income -
Interest Expense $92K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $12K
Income Before Tax -$12M
Income Tax Expense -$503
Interest And Debt Expense -
Net Income From Continuing Operations -$12M
Comprehensive Income Net Of Tax -
Ebit -$12M
Ebitda -$12M
Net Income -$12M

DWTX News

DWTX Profile

Dogwood Therapeutics, Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Dogwood Therapeutics, Inc. is an innovative biotechnology firm headquartered in Alpharetta, Georgia, dedicated to developing advanced antiviral therapies that target diseases linked to dysregulated immune responses from viral infections. The company boasts a robust pipeline of novel therapeutic candidates, leveraging state-of-the-art research to transform treatment approaches in the antiviral landscape. As Dogwood Therapeutics advances through preclinical and clinical stages, it aims to significantly improve patient outcomes and solidify its position as a leader in combating viral diseases.

WTO
+25.52%
$0.03
LPTX
+368.57%
$2.05
APLT
+30.18%
$0.28
AMIX
+58.18%
$1.15
KXIN
-7.64%
$0.28
NVDA
-1.87%
$186.60
ONDS
-12.88%
$6.25
CHR
-2.66%
$0.04
ASST
-3.70%
$1.04
TSLA
+1.13%
$408.92
GLMD
+0.96%
$1.05
PFE
+0.07%
$25.08
SOFI
-2.80%
$27.04
DVLT
+1.91%
$1.86
F
-2.35%
$12.88
PLUG
-7.12%
$2.08
INTC
-2.28%
$34.71
GNS
-9.87%
$0.77
QUBT
+8.49%
$11.50
ACHR
-5.83%
$7.42
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
DNN
-3.62%
$2.39
BYND
-3.70%
$1.04
BITF
+3.48%
$2.67
AMZN
-0.77%
$232.87
BMNR
-10.02%
$30.95
RIVN
-1.58%
$14.87
ETHD
+8.79%
$5.69
DFLI
-1.27%
$0.80
ASBP
-14.11%
$0.09
KVUE
-2.52%
$16.24
MARA
-4.00%
$11.51
NIO
-1.29%
$6.08
GOOGL
+3.11%
$285.02
ADAP
-15.14%
$0.05
SNAP
-4.55%
$8.18
HPE
-7.00%
$21.23
PLTR
-1.58%
$171.25
BURU
-13.34%
$0.21
RIG
+1.74%
$4.08
TLRY
-4.62%
$1.03
AAPL
-1.81%
$267.46
GPUS
-14.84%
$0.23
CIFR
-0.06%
$14.35
AAL
-3.29%
$12.34
RGTI
-3.10%
$24.69
GRAB
-1.47%
$5.33
WULF
+0.54%
$11.05
HOOD
-5.33%
$115.97
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AMD
-2.54%
$240.52
MSPR
+18.40%
$0.53
PLTD
+1.75%
$6.96
WBD
-1.25%
$22.74
BAC
-2.14%
$51.48
BTG
-2.68%
$3.99
CAN
-4.37%
$0.85
XPEV
-10.31%
$22.43
SRM
+53.27%
$10.30
T
-0.46%
$25.47
GOOG
+3.11%
$285.60
IREN
+2.24%
$47.41
NOK
-1.04%
$6.66
SMCI
-6.37%
$34.10
BBD
-1.63%
$3.62
AMC
-4.82%
$2.17
BTBT
-4.56%
$2.30
HIMS
-3.78%
$35.58
MU
-1.97%
$241.95
QBTS
-3.30%
$22.83
BTE
-4.43%
$3.02
OWL
-5.81%
$13.77
HBAN
-2.73%
$15.30
SOUN
-6.08%
$11.43
CRWV
-2.62%
$75.33
CSCO
-0.28%
$77.78
WLGS
-5.57%
$0.04
IONZ
-3.07%
$5.04
CLSK
-3.19%
$10.61
VALE
-1.05%
$12.17
MTSR
-0.35%
$70.50
NFLX
-0.83%
$110.29
EOSE
-5.79%
$13.00
ABEV
-0.39%
$2.54
APLD
-3.02%
$22.93
RXRX
-0.48%
$4.12
CLF
+2.23%
$10.97
SMR
-6.19%
$21.06
TWOH
0.00%
$0.00
IVVD
+20.85%
$2.84
CRCL
-6.47%
$76.59
AFMD
-34.94%
$0.18
AMCR
-0.35%
$8.45
QS
-3.57%
$12.95
KDP
-0.62%
$26.96
NBIS
+2.92%
$85.98
JOBY
-3.60%
$13.89
WTO
+25.52%
$0.03
LPTX
+368.57%
$2.05
APLT
+30.18%
$0.28
AMIX
+58.18%
$1.15
KXIN
-7.64%
$0.28
NVDA
-1.87%
$186.60
ONDS
-12.88%
$6.25
CHR
-2.66%
$0.04
ASST
-3.70%
$1.04
TSLA
+1.13%
$408.92
GLMD
+0.96%
$1.05
PFE
+0.07%
$25.08
SOFI
-2.80%
$27.04
DVLT
+1.91%
$1.86
F
-2.35%
$12.88
PLUG
-7.12%
$2.08
INTC
-2.28%
$34.71
GNS
-9.87%
$0.77
QUBT
+8.49%
$11.50
ACHR
-5.83%
$7.42
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
DNN
-3.62%
$2.39
BYND
-3.70%
$1.04
BITF
+3.48%
$2.67
AMZN
-0.77%
$232.87
BMNR
-10.02%
$30.95
RIVN
-1.58%
$14.87
ETHD
+8.79%
$5.69
DFLI
-1.27%
$0.80
ASBP
-14.11%
$0.09
KVUE
-2.52%
$16.24
MARA
-4.00%
$11.51
NIO
-1.29%
$6.08
GOOGL
+3.11%
$285.02
ADAP
-15.14%
$0.05
SNAP
-4.55%
$8.18
HPE
-7.00%
$21.23
PLTR
-1.58%
$171.25
BURU
-13.34%
$0.21
RIG
+1.74%
$4.08
TLRY
-4.62%
$1.03
AAPL
-1.81%
$267.46
GPUS
-14.84%
$0.23
CIFR
-0.06%
$14.35
AAL
-3.29%
$12.34
RGTI
-3.10%
$24.69
GRAB
-1.47%
$5.33
WULF
+0.54%
$11.05
HOOD
-5.33%
$115.97
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AMD
-2.54%
$240.52
MSPR
+18.40%
$0.53
PLTD
+1.75%
$6.96
WBD
-1.25%
$22.74
BAC
-2.14%
$51.48
BTG
-2.68%
$3.99
CAN
-4.37%
$0.85
XPEV
-10.31%
$22.43
SRM
+53.27%
$10.30
T
-0.46%
$25.47
GOOG
+3.11%
$285.60
IREN
+2.24%
$47.41
NOK
-1.04%
$6.66
SMCI
-6.37%
$34.10
BBD
-1.63%
$3.62
AMC
-4.82%
$2.17
BTBT
-4.56%
$2.30
HIMS
-3.78%
$35.58
MU
-1.97%
$241.95
QBTS
-3.30%
$22.83
BTE
-4.43%
$3.02
OWL
-5.81%
$13.77
HBAN
-2.73%
$15.30
SOUN
-6.08%
$11.43
CRWV
-2.62%
$75.33
CSCO
-0.28%
$77.78
WLGS
-5.57%
$0.04
IONZ
-3.07%
$5.04
CLSK
-3.19%
$10.61
VALE
-1.05%
$12.17
MTSR
-0.35%
$70.50
NFLX
-0.83%
$110.29
EOSE
-5.79%
$13.00
ABEV
-0.39%
$2.54
APLD
-3.02%
$22.93
RXRX
-0.48%
$4.12
CLF
+2.23%
$10.97
SMR
-6.19%
$21.06
TWOH
0.00%
$0.00
IVVD
+20.85%
$2.84
CRCL
-6.47%
$76.59
AFMD
-34.94%
$0.18
AMCR
-0.35%
$8.45
QS
-3.57%
$12.95
KDP
-0.62%
$26.96
NBIS
+2.92%
$85.98
JOBY
-3.60%
$13.89

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.